vs
Side-by-side financial comparison of HEALTHSTREAM INC (HSTM) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $79.7M, roughly 1.1× HEALTHSTREAM INC). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 7.4%). HEALTHSTREAM INC produced more free cash flow last quarter ($13.0M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 4.7%).
HealthStream Inc is a leading U.S.-based provider of workforce development, compliance, and training solutions tailored for the healthcare industry. It offers cloud-based platforms covering clinical skill training, talent management, patient safety education, and regulatory adherence tools, serving over 4,000 healthcare organizations including hospitals, clinics, and long-term care facilities nationwide.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
HSTM vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $79.7M | $86.8M |
| Net Profit | — | — |
| Gross Margin | — | 67.4% |
| Operating Margin | 3.0% | -84.7% |
| Net Margin | — | — |
| Revenue YoY | 7.4% | 17.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.09 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $79.7M | $86.8M | ||
| Q3 25 | $76.5M | $67.5M | ||
| Q2 25 | $74.4M | $60.0M | ||
| Q1 25 | $73.5M | $49.3M | ||
| Q4 24 | $74.2M | $73.7M | ||
| Q3 24 | $73.1M | $58.6M | ||
| Q2 24 | $71.6M | $31.1M | ||
| Q1 24 | $72.8M | $715.0K |
| Q4 25 | — | — | ||
| Q3 25 | $6.1M | $-91.3M | ||
| Q2 25 | $5.4M | $-111.7M | ||
| Q1 25 | $4.3M | $-116.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $5.7M | $-83.5M | ||
| Q2 24 | $4.2M | $-97.1M | ||
| Q1 24 | $5.2M | $-113.0M |
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | — |
| Q4 25 | 3.0% | -84.7% | ||
| Q3 25 | 9.9% | -140.7% | ||
| Q2 25 | 7.9% | -189.8% | ||
| Q1 25 | 6.0% | -245.8% | ||
| Q4 24 | 6.3% | -117.5% | ||
| Q3 24 | 8.9% | -152.1% | ||
| Q2 24 | 6.2% | -327.6% | ||
| Q1 24 | 7.8% | -16464.6% |
| Q4 25 | — | — | ||
| Q3 25 | 8.0% | -135.3% | ||
| Q2 25 | 7.2% | -186.2% | ||
| Q1 25 | 5.9% | -235.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 7.8% | -142.7% | ||
| Q2 24 | 5.8% | -312.2% | ||
| Q1 24 | 7.2% | -15800.8% |
| Q4 25 | $0.09 | — | ||
| Q3 25 | $0.20 | — | ||
| Q2 25 | $0.18 | $-0.33 | ||
| Q1 25 | $0.14 | $-0.36 | ||
| Q4 24 | $0.16 | $-0.24 | ||
| Q3 24 | $0.19 | $-0.28 | ||
| Q2 24 | $0.14 | $-0.34 | ||
| Q1 24 | $0.17 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $36.2M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $354.0M | $698.6M |
| Total Assets | $520.4M | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $36.2M | $297.0M | ||
| Q3 25 | $53.5M | $300.8M | ||
| Q2 25 | $52.1M | $301.2M | ||
| Q1 25 | $77.3M | $359.7M | ||
| Q4 24 | $59.5M | $323.8M | ||
| Q3 24 | $57.5M | $397.5M | ||
| Q2 24 | $46.1M | $412.5M | ||
| Q1 24 | $52.4M | $356.2M |
| Q4 25 | $354.0M | $698.6M | ||
| Q3 25 | $349.2M | $702.3M | ||
| Q2 25 | $350.6M | $698.5M | ||
| Q1 25 | $362.8M | $767.9M | ||
| Q4 24 | $359.4M | $710.4M | ||
| Q3 24 | $355.5M | $773.5M | ||
| Q2 24 | $349.2M | $768.5M | ||
| Q1 24 | $344.9M | $680.0M |
| Q4 25 | $520.4M | $913.2M | ||
| Q3 25 | $499.9M | $904.9M | ||
| Q2 25 | $500.1M | $907.4M | ||
| Q1 25 | $524.0M | $966.7M | ||
| Q4 24 | $510.8M | $910.4M | ||
| Q3 24 | $502.8M | $991.1M | ||
| Q2 24 | $499.6M | $964.3M | ||
| Q1 24 | $511.6M | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.2M | $-52.6M |
| Free Cash FlowOCF − Capex | $13.0M | $-61.9M |
| FCF MarginFCF / Revenue | 16.3% | -71.3% |
| Capex IntensityCapex / Revenue | 0.3% | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $59.6M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.2M | $-52.6M | ||
| Q3 25 | $18.0M | $-78.7M | ||
| Q2 25 | $5.0M | $-67.4M | ||
| Q1 25 | $27.1M | $-103.7M | ||
| Q4 24 | $11.2M | $-73.3M | ||
| Q3 24 | $19.1M | $-59.0M | ||
| Q2 24 | $6.5M | $-98.4M | ||
| Q1 24 | $20.9M | $-122.3M |
| Q4 25 | $13.0M | $-61.9M | ||
| Q3 25 | $17.9M | $-89.5M | ||
| Q2 25 | $2.7M | $-74.9M | ||
| Q1 25 | $26.0M | $-109.9M | ||
| Q4 24 | $11.0M | $-77.5M | ||
| Q3 24 | $18.8M | $-61.3M | ||
| Q2 24 | $6.3M | $-98.9M | ||
| Q1 24 | $20.2M | $-126.5M |
| Q4 25 | 16.3% | -71.3% | ||
| Q3 25 | 23.4% | -132.7% | ||
| Q2 25 | 3.6% | -124.9% | ||
| Q1 25 | 35.4% | -222.8% | ||
| Q4 24 | 14.8% | -105.1% | ||
| Q3 24 | 25.8% | -104.6% | ||
| Q2 24 | 8.8% | -317.9% | ||
| Q1 24 | 27.8% | -17685.3% |
| Q4 25 | 0.3% | 10.7% | ||
| Q3 25 | 0.1% | 16.1% | ||
| Q2 25 | 3.1% | 12.4% | ||
| Q1 25 | 1.4% | 12.6% | ||
| Q4 24 | 0.3% | 5.7% | ||
| Q3 24 | 0.4% | 3.9% | ||
| Q2 24 | 0.2% | 1.4% | ||
| Q1 24 | 1.0% | 583.4% |
| Q4 25 | — | — | ||
| Q3 25 | 2.96× | — | ||
| Q2 25 | 0.93× | — | ||
| Q1 25 | 6.25× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.34× | — | ||
| Q2 24 | 1.55× | — | ||
| Q1 24 | 4.01× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HSTM
| Subscription Services | $77.0M | 97% |
| Professional Services | $2.7M | 3% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
